

RESEARCH
Reliance Industries | Target: Rs 1,335 | +7% | ADD

Concerns on cyclicals

HDFC Bank | Target: Rs 2,510 | +6% | ADD

Mixed quarter

L&T Infotech | Target: Rs 2,010 | +33% | BUY

Client-specific challenges to hamper growth in FY20

SUMMARY
Reliance Industries

Reliance Industries' (RIL) Q1 FY20 EBITDA marginally beat estimates at Rs 213bn (+3% YoY, +2.3% QoQ). Key highlights: a) GRMs inline at US\$ 8.1/bbl; b) Petchem EBITDA at Rs88 bn (-4.4% YoY) beat estimates on higher polyester margins; c) in-line retail business EBITDA at Rs 20.5bn (+70% YoY); and d) RJio EBITDA at Rs49 bn (+9% QoQ). Outlook on cyclical businesses remains challenging, making us cut FY20E/FY21E earnings by 23.6%/18.4%, resulting in lower TP of Rs 1,335 (vs. Rs 1510).

[Click here for the full report.](#)

HDFC Bank

HDFC Bank's (HDFCB) Q1FY20 PAT at Rs 56bn (+21% YoY) was largely in line with our estimates. GNPA inched up to 1.4% but was stable ex-agri at 1.17%. The bank created contingent/additional general provisions worth Rs 1.7bn/Rs 0.9bn which led to a sharp rise in provisions for Q1. Loan growth at 17% YoY slipped to a 10-quarter low following a rundown of corporate loans due to repayments. Gross impaired assets for HDB Financial Services rose 50bps QoQ to 2.3% of loans. Maintain ADD with a Mar'20 TP of Rs 2,510.

[Click here for the full report.](#)

TOP PICKS
LARGE-CAP IDEAS

Company	Rating	Target
Cipla	Buy	630
GAIL*	Buy	245
ONGC	Buy	230
TCS	Add	2,360
HPCL	Sell	210

*GAIL target price is adjusted for the 1:1 bonus issue

MID-CAP IDEAS

Company	Rating	Target
Balkrishna Ind	Buy	1,290
Future Supply	Buy	780
Greenply Industries	Buy	245
Laurus Labs	Buy	495
PNC Infratech	Buy	235

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	2.02	(2bps)	(7bps)	(81bps)
India 10Y yield (%)	6.39	4bps	(54bps)	(140bps)
USD/INR	68.96	(0.2)	1.3	0.1
Brent Crude (US\$/bbl)	61.93	(2.7)	1.6	(14.7)
Dow	27,223	0	4.3	8.6
Shanghai	2,901	(1.0)	0.5	4.6
Sensex	38,897	(0.8)	(0.2)	7.0
India FII (US\$ mn)	17 Jul	MTD	CYTD	FYTD
FII-D	(88.5)	1,240.0	2,668.3	2,123.6
FII-E	(12.5)	(834.6)	10,504.2	3,659.0

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



L&T Infotech

L&T Infotech (LTI) reported a sedate Q1FY20 with 1% QoQ CC revenue growth and 16% EBIT margins against our estimate of 1.5% growth and 16.9% margins. Management indicated that top account challenges have bottomed out, though revenue from another key BFS client is on the decline. We prune FY20/FY21 EPS by 6%/7% and roll forward to a new Jun'20 TP of Rs 2,010 (vs. Rs 2,100). FY20 challenges are likely to be transient and we build in a return to double-digit growth in FY21. Reiterate BUY on solid long-term business prospects.

[Click here](#) for the full report.

ADD
TP: Rs 1,335 | ▲ 7%

RELIANCE INDUSTRIES | Oil & Gas

21 July 2019

Concerns on cyclicals

Reliance Industries’ (RIL) Q1 FY20 EBITDA marginally beat estimates at Rs 213bn (+3% YoY, +2.3% QoQ). Key highlights: a) GRMs inline at US\$ 8.1/bbl; b) Petchem EBITDA at Rs88 bn (-4.4% YoY) beat estimates on higher polyester margins; c) in-line retail business EBITDA at Rs 20.5bn (+70% YoY); and d) RJio EBITDA at Rs49 bn (+9% QoQ). Outlook on cyclical businesses remains challenging, making us cut FY20E/FY21E earnings by 23.6%/18.4%, resulting in lower TP of Rs 1,335 (vs. Rs 1510).

Rohit Ahuja | Harleen Manglani

research@bobcaps.in


Investment in Tower Invt: RIL announced Rs250 bn investment by Brookfield in the Tower Invt (RJIPL). This would be in the form of quasi equity, against which RJIPL will raise another Rs110 bn debt to clear out the entire Rs370 bn liability associated with this asset. The deal for the Fibre assets is expected on similar lines in Q2 FY20 (Invt carrying Rs1,660 bn liabilities).

Ticker/Price	RIL IN/Rs 1,249
Market cap	US\$ 107.4bn
Shares o/s	5,927mn
3M ADV	US\$ 159.5mn
52wk high/low	Rs 1,418/Rs 1,016
Promoter/FPI/DII	47%/24%/28%

Source: NSE

Cyclicals outlook remains cloudy: While refining margins were in-line at US\$8.1/bbl, guidance on impact from IMO regulations seems unclear. We cut GRM estimates to US\$10-11/bbl (from US\$12/bbl) for FY20/21, based on current trend of low GRMs. Petrochemicals earnings outperformed estimates on better margins. However, production declined (with utilisation at ~90% levels across product categories), as demand concerns outweigh. We trim both production and margin estimates for Petrochemicals by 10%/20% for FY20/21.

STOCK PERFORMANCE



Source: NSE

RJio gaining ground, retail surges: RJio touched 331 mn in gross subscribers, while ARPU were below estimates at Rs122. EBITDA was still in-line at Rs49bn (+8.7% QoQ), on Rs3.7 bn gain from IND AS 116. Retail EBITDA surged to Rs 20.5bn (+70% YoY) led by core margins of 8.9% (+130bps YoY).

Maintain ADD: Uncertainty on cyclicals (~65% of EBITDA in Q1 FY20) raises concerns on RIL’s earnings outlook, capping upside.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19P	FY20E	FY21E	FY22E
Adj. net profit (Rs mn)	352,869	398,370	465,776	587,439	757,409
Adj. EPS (Rs)	59.6	67.2	78.6	99.1	127.8
Adj. EPS growth (%)	17.4	12.8	16.9	26.1	28.9
Adj. ROAE (%)	12.4	11.7	11.7	13.2	14.9
Adj. P/E (x)	21.0	18.6	15.9	12.6	9.8
EV/EBITDA (x)	14.7	10.9	10.6	8.3	6.9

Source: Company, BOBCAPS Research



ADD

TP: Rs 2,510 | ▲ 6%

HDFC BANK

| Banking

| 20 July 2019

Mixed quarter

HDFC Bank's (HDFCB) Q1FY20 PAT at Rs 56bn (+21% YoY) was largely in line with our estimates. GNPA inched up to 1.4% but was stable ex-agri at 1.17%. The bank created contingent/additional general provisions worth Rs 1.7bn/Rs 0.9bn which led to a sharp rise in provisions for Q1. Loan growth at 17% YoY slipped to a 10-quarter low following a rundown of corporate loans due to repayments. Gross impaired assets for HDB Financial Services rose 50bps QoQ to 2.3% of loans. Maintain ADD with a Mar'20 TP of Rs 2,510.

Vikesh Mehta

research@bobcaps.in

Loan growth disappoints: At 17% YoY, HDFCB's loan growth was at a 10-quarter low, due to slower growth in both corporate (~18%) and retail (~16%) loans. Excluding the tepid vehicle finance segment, retail advances grew 19.3%.

Buffers to strengthen balance sheet: Slippages rose to ~Rs 42bn (Rs 36bn in Q4), which led to a 4bps QoQ increase in GNPA ratio to 1.4%. Provisions shot up 40% QoQ as specific provisions were stepped up on the unsecured portfolio, contingent provisions worth Rs 1.65bn were created, and additional general provisions were made on standard assets in the NBFC/HFC categories.


Management highlighted the rise in customer leverage, frequency of borrowing and ticket size for the industry in the personal loan segment.

Poor show by HDB Fin Services: HDB's gross impaired loans increased to 2.3% due to stress in its CE/CV portfolio and higher losses on repossession. NII growth slowed to 12.9% YoY as NIM dipped 30-40bps.

Maintain ADD: We like HDFCB for its strong processes, risk management practices and stable asset quality, but do see risks emerging for the bank on NII (from slowing loan growth) and margins (declining CASA ratio, tepid growth in high-yield unsecured retail credit). Retain ADD.

Ticker/Price	HDFCB IN/Rs 2,376
Market cap	US\$ 93.9bn
Shares o/s	2,723mn
3M ADV	US\$ 100.8mn
52wk high/low	Rs 2,503/Rs 1,885
Promoter/FPI/DII	27%/39%/34%

Source: NSE

STOCK PERFORMANCE

Source: NSE

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Adj. net profit (Rs mn)	174,867	210,782	258,229	318,769	382,952
EPS (Rs)	67.8	79.3	94.8	117.1	140.6
P/E (x)	35.0	30.0	25.1	20.3	16.9
P/BV (x)	5.8	4.3	3.8	3.3	2.9
ROA (%)	1.8	1.8	1.9	1.9	1.8
ROE (%)	17.9	16.5	16.2	17.6	18.4

Source: Company, BOBCAPS Research



BUY

TP: Rs 2,010 | ▲ 33%

L&T INFOTECH

| IT Services

| 20 July 2019

Client-specific challenges to hamper growth in FY20

L&T Infotech (LTI) reported a sedate Q1FY20 with 1% QoQ CC revenue growth and 16% EBIT margins against our estimate of 1.5% growth and 16.9% margins. Management indicated that top account challenges have bottomed out, though revenue from another key BFS client is on the decline. We prune FY20/FY21 EPS by 6%/7% and roll forward to a new Jun'20 TP of Rs 2,010 (vs. Rs 2,100). FY20 challenges are likely to be transient and we build in a return to double-digit growth in FY21. Reiterate BUY on solid long-term business prospects.

Ruchi Burde

research@bobcaps.in

Soft operating performance: Revenues stood at US\$ 357mn for the Jun'19 quarter, rising 1% QoQ CC vs. 1.5% estimated. EBIT margins also fell short, contracting 170bps QoQ to 16%. We highlight that the muted revenue performance stemmed from a seasonal dip in India (manufacturing) revenue; international revenue grew at a healthy 2.2% QoQ (in dollar terms). Moreover, BFS revenue increased 1.4% QoQ CC despite earlier indications of softness in the top account.

Ticker/Price	LTI IN/Rs 1,516
Market cap	US\$ 3.9bn
Shares o/s	175mn
3M ADV	US\$ 4.4mn
52wk high/low	Rs 1,987/Rs 1,437
Promoter/FPI/DII	75%/8%/10%

Source: NSE

PAT at Rs 3.5bn was down 6.1% QoQ and 1.6% YoY, below our estimate due to the operational miss. Cash flow from operations stood at Rs 3.3bn with a 94% PAT to CFO conversion ratio.

STOCK PERFORMANCE



Source: NSE

Large deal wins continue: LTI added yet another new client (in the insurance vertical) with a TCv of US\$ 44mn, highlighting its strong service offerings. This also marks the eighth consecutive quarter of large deal wins.

Retain BUY: Account-specific constraints could pose transient growth challenges in FY20, but we believe LTI has laid the foundation for structural long-term growth. Retain BUY with a revised Jun'20 TP of Rs 2,010, based on an unchanged one-year forward P/E of 20x.

KEY FINANCIALS

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Adj. net profit (Rs mn)	11,124	15,157	14,980	17,238	18,717
Adj. EPS (Rs)	63.5	86.5	85.5	98.4	106.8
Adj. EPS growth (%)	(8.2)	36.1	(1.1)	15.1	8.6
Adj. ROAE (%)	31.8	34.6	28.1	27.5	25.6
Adj. P/E (x)	23.9	17.5	17.7	15.4	14.2
EV/EBITDA (x)	22.0	13.9	13.9	11.3	9.8

Source: Company, BOBCAPS Research



Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

ADD – Expected return from >+5% to +15%

REDUCE – Expected return from -5% to +5%

SELL – Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 30 June 2019, out of 76 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 43 have BUY ratings, 15 are rated ADD, 10 are rated REDUCE and 8 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance, wealth management and portfolio management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not

provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.